Increasing Emphasis on Early Disease Detection and Prevention
The earlier a disease is diagnosed, the more likely it is that it can be cured or successfully managed. Early disease detection helps people plan on their health and support needs, and financial and legal matters. It also helps their families receive practical information, advice, and guidance, as they face new challenges. Genetic diseases, such as cystic fibrosis, sickle cell anemia, and Tay-Sachs disease, are inherited disorders. Carrier testing for such diseases can provide information about a couple’s risk of having a child with a genetic condition. Identification of the risk before the onset of symptoms is called predictive/pre-symptomatic testing. Many genetic disorders can be detected early in pregnancy. So, the consumer demand for safe and effective carrier tests is fueling the growth of the market.
The others factors, such as increasing demand for personalized medicine and increasing application of screening tests in genetic disorders, are also fueling the growth of the carrier screening market.
Social and Ethical Implications of Carrier Screening
Carrier screening tests have long-term implications for an individual and his/her family. The screening tests may raise the issue of stigmatization of a certain population, as mutations for certain diseases may have a higher prevalence in a certain ethnic population. Two major factors are associated with potential stigma, including severity of the deleterious gene and visibility of the carrier status. The carriers refrain themselves from childbearing or donating egg or sperm. It also raises obligations regarding education and counseling. It is also an issue that children may be provided with information that they would rather not have at the age of consent.
Parents may reject children with abnormal genes or may be less willing to devote financial resources to their education or other benefits for them. Positive results of carrier screening may cause the individual to be viewed as uninsurable, unemployable, and unmarriageable. In a lot of these cases, physicians have to face a certain degree of ethical tension to protect the confidentiality of the individual who has consented to a test. All the above ethical and social issues related to carrier screening impede the growth of the market. The other factors, such as high cost and reimbursement issues, are also hindering the market growth.
Asia-Pacific is projected to register the Highest CAGR
Asia-Pacific is expected to record the highest CAGR of 10.3% during the forecast period. Increasing investments in R&D activities, production, and rising indigenous production are propelling the market in Asia-Pacific. However, the North American region holds the largest share in the carrier screening market.
Key Developments in the Market
- September 2017: Thermo Fisher Scientific launched its new PureLink Fast Low-Endotoxin Plasmid Purification Midi and Maxi Kits for DNA isolation.
- August 2017: Luminex Corporation collaborated with Sutter Health Labs to improve patient care in the health network, including a range of conditions, including cystic fibrosis, gastrointestinal illness, and respiratory tract infections.
Reasons to Purchase the Report
- Current and future market outlook for carrier screening in developed and emerging markets
- Analyzing various perspectives on the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- The regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- Three-month analyst support, along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1.1 Increasing Emphasis on Early-disease Detection and Prevention
6.1.2 Growing Demand for Personalized Medicine
6.1.3 Increasing Application of Screening Tests in Genetic Disorders
6.2.1 Social and Ethical Implications of Carrier Screening
6.2.2 High Costs of Carrier Testing
6.2.3 Reimbursement Issues
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation - by Test Type
7.1.1 Molecular Screening Test
7.1.2 Biochemical Screening Test
7.2 Segmentation - by Disease Type
7.2.1 Cystic Fibrosis
7.2.3 Gaucher Disease
7.2.4 Sickle Cell Disease
7.2.5 Spinal Muscular Atrophy
7.2.6 Other Autosomal Recessive Genetic Disorders
7.3 Segmentation - by Geography
7.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 Australia & New Zealand
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
7.3.4 Middle East & Africa
188.8.131.52 South Africa
184.108.40.206 Rest of the Middle East & Africa
7.3.5 South America
220.127.116.11 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 23Andme Inc.
9.2 Abbott Laboratories
9.3 Roche Holding Ag
9.4 Cepheid (Danaher Corporation)
9.5 Illumina Inc.
9.6 Luminex Corporation
9.7 Sequenom Inc. (Laboratory Corporation of America Holdings [Labcorp])
9.8 Myriad Genetics
9.9 Autogenomics Inc.
9.10 Thermo Fisher Scientific Inc.
10. Future of the Market
- 23ANDME INC.
- ABBOTT LABORATORIES
- ROCHE HOLDING AG
- CEPHEID (DANAHER CORPORATION)
- ILLUMINA INC.
- LUMINEX CORPORATION
- SEQUENOM INC. (LABORATORY CORPORATION OF AMERICA HOLDINGS [LABCORP])
- MYRIAD GENETICS
- THERMO FISHER SCIENTIFIC INC.
- AUTOGENOMICS INC.